Literature DB >> 25782173

Bladder cancer: Urinary EGFR and EpCAM predict cancer-specific survival.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25782173     DOI： 10.1038/nrurol.2015.55

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM.

Authors:  R T Bryan; H L Regan; S J Pirrie; A J Devall; K K Cheng; M P Zeegers; N D James; M A Knowles; D G Ward
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640
  1 in total
  1 in total

1.  Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.

Authors:  Mei Peng; Yanjun Huang; Ting Tao; Cai-Yun Peng; Qiongli Su; Wanjun Xu; Kwame Oteng Darko; Xiaojun Tao; Xiaoping Yang
Journal:  Sci Rep       Date:  2016-06-23       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.